Home

ECNP 2022

Progress in Mind Resource Center reports from the 35th European College of Neuropsychopharmacology Congress 2022.

Our reporters are in Vienna and online to capture some of the best content from the Hybrid Congress just for you:

Daily congress highlights
In-depth updates on the latest research in Psychiatry
Expert views from a global network KOL's

Anxiety, Depression

Read time: 5 min

Satellite symposium

The role of sleep disorders in depression and anxiety

In the symposium ‘Assessment and management of sleep disorders in anxious and depressed...

Read time: 5 min

Satellite symposium

Targeting trace amine-associated receptors (TAARs) to treat schizophrenia

In this symposium titled ‘Novel TAARgets for stabilizing neural circuits in schizophrenia...

Read time: 5 min

Satellite symposium

The glutamate model of psychosis

In the Keynote Session of the 35th ECNP Congress in Vienna, Austria (15th−18th Oct),...

Read time: 7 min

New findings in aging, pain, depression, suicide, anxiety and schizophrenia

A number of studies were presented at the 35th ECNP Congress in Vienna, Austria (15th−18th...

Read time: 6 min

Satellite symposium

Cognitive impairment, as a key symptom of schizophrenia

In this symposium presented at the 35th ECNP Congress in Vienna, Austria (15th−18th Oct),...

Bipolar, Schizophrenia

Read time: 3 min

Cognition in schizophrenia and bipolar disorder: Potential mechanisms and possible therapies

At the 35th ECNP Congress in Vienna, Austria (15th−18th Oct), Dr Ingrid Melle (University of...

Anxiety, Depression

Read time: 4 min

Satellite symposium

Improving functioning as a treatment goal in comorbid major depressive disorder and generalized anxiety disorder

At the 35th ECNP Congress in Vienna, Austria (15−18th October), in a symposium...

Other conferences

Read time: Read time: 1 min

Read time: Read time: 1 min

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind Greece Continue to Progress in Mind South East Asia Continue to Progress in Mind Middle East & Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Japan RC Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine Continue to Progress in Mind Belgium & Luxembourg Continue to Progress in Mind Switzerland Continue to Progress in Mind Germany Continue to Progress in Mind Austria

You are leaving Progress in Mind

Continue to

Cancel

Progress in Mind Netherlands

Accept Cancel

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intended for health care professionals.

All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country